PTC Therapeutics, Inc. (PTCT): Operating Income
$866.93M
Year ended 2025-12-31
$125.60M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $866.93M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$302.57M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$439.50M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$447.41M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$374.44M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$431.77M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | -$241.16M | n/m | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | -$115.69M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$64.29M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$132.06M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$167.13M | n/m | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | -$99.41M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$45.40M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$26.81M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $30.58M | n/a | 2014-03-06, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $866.93M | n/m |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $194.40M | +76.0% |
| Alkermes plc. (ALKS) | 2025-12-31 | $253.96M | -39.6% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$699.78M | n/m |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $1.56B | +20.7% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $262.00M | +589.5% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $309.41M | -8.1% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $104.81M | -54.6% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $394.10M | +58.1% |
Compare PTCT, PAHC, ALKS, SRPT side by side · Screen every company in Pharmaceutical Preparations ↗